Website stats for Remicade - remicade.com
Only your doctor can recommend a course of treatment after checking your health condition. REMICADE (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those years and older, have had serious infections which include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body or...
remicade.com was registered 2 decades 6 years ago. It has a alexa rank of #3,678,539 in the world. It is a domain having .com extension. It is estimated worth of $ 240.00 and have a daily income of around $ 1.00. As no active threats were reported recently, remicade.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 238 |
| Daily Pageviews: | 476 |
Estimated Valuation
| Income Per Day: | $ 1.00 |
| Estimated Worth: | $ 240.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 3,678,539 |
| PageSpeed Score: | 89 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
99.86.3.71
Hosted Country:
DE
Location Latitude:
50.1155Location Longitude:
8.68417Traffic Classification
| Total Traffic: | No Data |
| Direct Traffic: | No Data |
| Referral Traffic: | No Data |
| Search Traffic: | No Data |
| Social Traffic: | No Data |
| Mail Traffic: | No Data |
| Display Traffic: | No Data |
Search Engine Results For remicade.com
Infliximab - Wikipedia
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune ...
Remicade Intravenous: Uses, Side Effects, Interactions, Pictures ...
This medication is used to treat certain types of arthritis (rheumatoid arthritis, arthritis of the spine, psoriatic arthritis), certain bowel diseases (Crohn's disease, ...
REMICADE (infliximab) Label - FDA
including REMICADE. All REMICADE cases were reported in patients with Crohn's disease or ulcerative colitis, the majority of whom were adolescent or young ...
FDA approves Inflectra, a biosimilar to Remicade | FDA
Apr 5, 2016 ... FDA approves Inflectra, a biosimilar to Remicade ... The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple ...
Inflectra vs. Remicade Rx Treatment for Crohn's and Ulcerative ...
Oct 17, 2019 ... Inflectra (infliximab-dyyb) for Injection and Remicade (infliximab) are used to reduce signs and symptoms of Crohn's disease, pediatric Crohn's ...
REMICADE® Receives FDA Approval as First Biologic Treatment for ...
Horsham, PA (September 23, 2011) – Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE® ...
Remicade - Digestive Diseases
Remicade® (infliximab) is a TNF inhibitor, a monoclonal antibody against tumor necrosis factor alpha (TNF-α), that is prescribed for the treatment of several ...
Remicade | European Medicines Agency
Remicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are ...
Medication Guide: Infliximab (Remicade)
Infliximab (Remicade). INFLIXIMAB (Remicade) is a chimeric (part mouse, part human) monoclonal antibody that blocks activity of a key biologic response ...
Official Consumer Website for REMICADE® (infliximab) | REMICADE®
Learn about treatment with REMICADE® across all uses on the official patient website. See full Product & Safety Info, including Boxed Warnings.
Remicade Powder For Solution For Injection Drug Information, Side ...
Remicade Powder for solution for injection drug summary. Find medication information including related drug classes, side effects, patient statistics and answers ...
Remicade, Inflectra (infliximab) dosing, indications, interactions ...
Medscape - Rheumatoid arthritis, inflammatory bowel-specific dosing for Remicade, Inflectra (infliximab), frequency-based adverse effects, comprehensive ...
Infliximab Injectable (Avsola, Inflectra®, Remicade ... - EmblemHealth
Aug 14, 2020 ... Failed trial of Remicade prior to using Avsola, Inflectra or Renflexis. Site of Care Criteria. Home (Place of Service 12), an ambulatory infusion ...
Two Studies Reveal Differences In Real-World Treatment Patterns In ...
Nov 14, 2016 ... REMICADE® has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis, ...
REMICADE- infliximab injection, powder, lyophilized, for ... -...
Patients treated with REMICADE are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ...
Remicade (Infliximab) - Side Effects, Interactions, Uses, Dosage ...
Jul 24, 2020 ... Remicade (Infliximab) ... Infliximab is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and severe or disabling plaque ...
Remicade (Infliximab) Fast facts about Remicade Financial assistance
- https://singerderm.com/wp-content/uploads/2019/04/remicade_fact_sheet_0-1.pdf
Remicade is used to treat psoriasis and psoriatic arthritis (together called psoriatic disease). How effective is it? Remicade helps to stop inflammation in the skin,.
Side Effects Of Remicade (Infliximab) - Verywell Health
Some potential side effects of Remicade (infliximab), a TNF-blocker drug that is used to treat Crohn's disease and ulcerative colitis.
REMICADE (infliximab) - American Infusion Centers
Remicade (infliximab) is a drug that reduces inflammation caused by the effects of tumor necrosis factor alpha, a substance produced in the body.
Centocor Announces REMICADE(R) (Infliximab) Milestone With ...
REMICADE is the global market share leader among TNF-alpha therapies and is the only biologic drug indicated for the treatment of both rheumatoid arthritis (RA) ...
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | 2 | H2 Headings: | 3 |
| H3 Headings: | Not Applicable | H4 Headings: | Not Applicable |
| H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
| Total IFRAMEs: | 1 | Total Images: | 14 |
| Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| moderately to | 35 | 1.176 % | No |
| severely active | 35 | 1.176 % | No |
| to severely | 35 | 1.176 % | No |
| and symptoms | 16 | 0.537 % | No |
| signs and | 16 | 0.537 % | No |
| ulcerative colitis | 16 | 0.537 % | No |
| Adult moderately | 15 | 0.504 % | No |
| active ulcerative | 14 | 0.47 % | No |
| reduce signs | 14 | 0.47 % | No |
| Can reduce | 14 | 0.47 % | No |
| such as | 12 | 0.403 % | No |
| adult patients | 12 | 0.403 % | No |
| patients with | 12 | 0.403 % | No |
| your doctor | 12 | 0.403 % | No |
| Adult active | 10 | 0.336 % | No |
| arthritis Adult | 10 | 0.336 % | No |
| Pediatric moderately | 10 | 0.336 % | No |
| of the | 10 | 0.336 % | No |
| in adult | 10 | 0.336 % | No |
| you have | 10 | 0.336 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| moderately to severely active | 35 | 1.176 % | No |
| Adult moderately to severely | 15 | 0.504 % | No |
| reduce signs and symptoms | 14 | 0.47 % | No |
| to severely active ulcerative | 14 | 0.47 % | No |
| severely active ulcerative colitis | 14 | 0.47 % | No |
| Can reduce signs and | 14 | 0.47 % | No |
| with moderately to severely | 10 | 0.336 % | No |
| Pediatric moderately to severely | 10 | 0.336 % | No |
| in adult patients with | 10 | 0.336 % | No |
| induce and maintain remission | 8 | 0.269 % | No |
| well to other therapies | 8 | 0.269 % | No |
| responded well to other | 8 | 0.269 % | No |
| to severely active Crohn’s | 7 | 0.235 % | No |
| severely active Crohn's disease | 7 | 0.235 % | No |
| severely active rheumatoid arthritis | 7 | 0.235 % | No |
| to severely active Crohn's | 7 | 0.235 % | No |
| severely active Crohn’s disease | 7 | 0.235 % | No |
| to severely active rheumatoid | 7 | 0.235 % | No |
| symptoms and induce and | 6 | 0.202 % | No |
| and symptoms and induce | 6 | 0.202 % | No |
Websites Hosted on Same IP (i.e. 99.86.3.71)
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Content-Type: text/html
Content-Length: 52995
Connection: keep-alive
Last-Modified: Thu, 31 Dec 2020 13:10:05 GMT
Server: AmazonS3
Date: Sun, 04 Apr 2021 15:19:05 GMT
Cache-Control: max-age=3600
ETag: "988c08814ff4a5c114c5ef6221b614bb"
X-Cache: Hit from cloudfront
Via: 1.1 2ef0748a2a8fca13fd6065b6b046c33c.cloudfront.net (CloudFront)
X-Amz-Cf-Pop: FRA6-C1
X-Amz-Cf-Id: Hr8Z1H7CSig_VfHH5oy8WQWAMpsOuSfb4J85Txiqgj04crrmBxMfqg==
Age: 2772
Domain Information
| Domain Registrar: |
Key-Systems GmbH
|
|---|---|
| Registration Date: | 1998-06-24 2 decades 6 years 3 months ago |
| Last Modified: | 2020-05-22 4 years 4 months 1 week ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| ns1.jnj.com | |
148.177.2.10 |  United States |
| ns3.jnj.com | |
148.177.130.197 | United States |
| ns5.jnj.com | |
199.65.212.10 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| dyb1neiopminw.cloudfront.net | A | 297 |
IP: 99.86.3.71 |
| dyb1neiopminw.cloudfront.net | A | 297 |
IP: 99.86.3.74 |
| dyb1neiopminw.cloudfront.net | A | 297 |
IP: 99.86.3.102 |
| dyb1neiopminw.cloudfront.net | A | 297 |
IP: 99.86.3.3 |
| dyb1neiopminw.cloudfront.net | NS | 86400 |
Target: ns-1985.awsdns-56.co.uk |
| dyb1neiopminw.cloudfront.net | NS | 86400 |
Target: ns-569.awsdns-07.net |
| dyb1neiopminw.cloudfront.net | NS | 86400 |
Target: ns-1312.awsdns-36.org |
| dyb1neiopminw.cloudfront.net | NS | 86400 |
Target: ns-149.awsdns-18.com |
| remicade.com | CNAME | 1797 |
Target: dyb1neiopminw.cloudfront.net |
| dyb1neiopminw.cloudfront.net | SOA | 300 |
MNAME: ns-1312.awsdns-36.org RNAME: awsdns-hostmaster.amazon.com Serial: 1 Refresh: 7200 Retry: 900 Expire: 1209600 |
Full WHOIS Lookup
Registry Domain ID:
4490150_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.rrpproxy.net
Registrar URL:
http://www.key-systems.net
Updated Date:
2020-05-22T15:00:34Z
Creation Date:
1998-06-24T04:00:00Z
Registry Expiry Date:
2021-06-23T04:00:00Z
Registrar: Key-Systems GmbH
Registrar
IANA ID: 269
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
+49.68949396850
Domain Status: clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Name Server:
NS1.JNJ.COM
Name Server: NS3.JNJ.COM
Name Server:
NS5.JNJ.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy
Complaint Form: https://www.icann.org/wicf/
>>> Last update of
whois database: 2021-04-04T16:05:09Z
Similarly Ranked Websites
Best Offline, Online training Institutes, Training 247
Training 247. Best Offline, Online training Institutes in hyderabad, Bangalore, Pune. Contact us for training course content, fees and Certification details.
3,678,644 
$ 240.00
أقوي كوبونات واكواد خصم المتاجر العربية فعالة ومحدثة يوميا | يلا كوبون
موقع يلا كوبون متخصص فى تقديم احدث كوبونات واكواد الخصم من اشهر المتاجر مثل كود خصم نون، كود خصم نمشي ، كوبون خصم سوق كوم ، كوبون خصم Shein والكثير من عروض وكوبونات المتاجر .
3,678,664 $ 240.00
Internal Medicine Associates, LLC • 201 East Huron Street •...
Internal Medicine Associates, LLC, affiliated with Northwestern Memorial Hospital
3,678,717 $ 240.00
ΣΩΤΗΡΙΟΥ στον Πειραιά- Είδη κάμπινγκ - Κατάδυσης - Ταξιδιού -...
ΣΩΤΗΡΙΟΥ στον Πειραιά- Είδη κάμπινγκ - Κατάδυσης - Ταξιδιού - Καπέλα - Νήματα - Κεντήματα.
3,678,753 $ 240.00